Search

Displaying results 4811 - 4820 of 10000 in total
  1. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    REN-850

    go.drugbank.com/drugs/DB05912
    Experimental

    REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.

  3. Drug

    Ellagic acid

    go.drugbank.com/drugs/DB08846
    Investigational

    Ellagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement … In pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also present in vegetables.

  4. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.

  5. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

    Categories: Dopamine D2 Receptor Antagonists
  8. Drug

    Amodiaquine

    go.drugbank.com/drugs/DB00613
    ApprovedInvestigational

    A 4-aminoquinoquinoline compound with anti-inflammatory properties.

  9. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  10. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. … People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.